Peter Martin

11.7k citations

222 papers · 4.2k indexed · h-index 35

Impact in

Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research
Pathology and Forensic Medicine top 0.2%
- Lymphoma Diagnosis and Treatment

Papers in

Pathology and Forensic Medicine 165
- Lymphoma Diagnosis and Treatment 162
Genetics 87
- Chronic Lymphocytic Leukemia Research 86

Co-authors: John P. Leonard Morton Coleman Richard R. Furman Jia Ruan Rebecca Elstrom Scott Ely Selina Chen‐Kiang Paul J. Christos
Journals: Blood (79 papers)Journal of Clinical Oncology (21 papers)Hematological Oncology (7 papers)Blood Advances (6 papers)Annals of Oncology (6 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Peter Martin

207 papers receiving 4.2k citations

Peers

Countries citing papers authored by Peter Martin

Since Specialization

Citations

This map shows the geographic impact of Peter Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Martin more than expected).

Fields of papers citing papers by Peter Martin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Martin. The network helps show where Peter Martin may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Martin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Martin Line = papers co-authored together Peter Martin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Perturbation of NAD(P)H metabolism with the Lb NOX xenotopic tool extends lifespan and mitigates age-related changes Science Advances ·E.M. Hay, Xingxiu Pan, Choujtani ، Khadija, Peter Martin, Muhammad Rauf, 裕二渡邊, مجید تبیانیان, Matilde Gonzalez Preciado, J. Patel, 則孝柘植, Markus K. Klose, Geraldine White, Valentin Cracan, Andrey A. Parkhitko	2026	0
2	Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma Blood Advances ·Sarah C. Rutherford, Jun Yin, Levi Pederson, Kristie A. Blum, Peter Martin, Sin‐Ho Jung, Barbara Grant, Cara A. Rosenbaum, Bruce D. Cheson, Nancy L. Bartlett, Sumithra J. Mandrekar, John P. Leonard	2024	2
3	MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses Blood ·Jia Ruan, David A. Bond, Bijal Shah, John N. Allan, Sarah C. Rutherford, Caitlin Gribbin, Zhengming Chen, 宏笠次, Sadia Sultana, Emile Edmond Ollivier, Wayne Tam, Bhavneet Bhinder, Michael Sigouros, Giorgio Inghirami, Selina Chen‐Kiang, Olivier Elemento, Kami J. Maddocks, John P. Leonard, Peter Martin	2024	2
4	Leveraging SMARCA4 Dependency of Mantle Cell Lymphomas to Overcome BTK Inhibitor Resistance Blood ·Hassan Najam Ali, Nicole Hoffman, Selina Chen‐Kiang, Caitlin Gribbin, Peter Martin, Jihye Paik	2024	0
5	Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study Blood ·Jacqueline Wang, Jihao Zhou, Nadine Ilunga, Han W. Tun, Javier Muñoz, Jonas Paludo, Muhamad Alhaj Moustafa, Steven R. Hwang, Noelia Soriano Conesa, Catherine Diefenbach, Jia Ruan, Peter Martin, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Yucai Wang	2024	0
6	Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma. Journal of Clinical Oncology ·Yucai Wang, Melissa C. Larson, Anita Kumar, Brian T. Hill, David A. Bond, Brad S. Kahl, Alexey V. Danilov, Reid W. Merryman, Natalie S. Grover, Aung M. Tun, Sabarish Ayyappan, Georgios Pongas, Craig A. Portell, Javier Muñoz, Patrick M. Reagan, Muhamad Alhaj Moustafa, Priyanka A. Pophali, Irl Brian Greenwell, Jonathon B. Cohen, Peter Martin	2024	1
7	Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma Blood ·Juan Pablo Alderuccio, Isildinha M. Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R. Chapman, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos	2023	6
8	Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis Blood Advances ·Danny Luan, Gerald C. Dudgeon, Ahmed Toure, Christopher R. Flowers, Brian K. Link, Jonathan W. Friedberg, Jonathon B. Cohen, Brad S. Kahl, Izidore S. Lossos, Loretta J. Nastoupil, Matthew J. Maurer, James R. Cerhan, Peter Martin	2022	3
9	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas Cancer Research ·M. Nieves Calvo-Vidal, Nahuel Zamponi, Jan Krumsiek, YH Xu, María V. Revuelta, Jude M. Phillip, Rossella Marullo, Ekaterina Tikhonova, Nikita Kotlov, Jayeshkumar Patel, Shao Ning Yang, Lucy Yang, Tony Taldone, Catherine Thiéblemont, John P. Leonard, Peter Martin, Giorgio Inghirami, Gabriela Chiosis, Scott R. Manalis, Leandro Cerchietti	2021	19
10	Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL Blood ·Peter Martin, Nancy L. Bartlett, Julio C. Chávez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, Julie Théroux-Séguin, Chengqing Wu, 夏渌, María V. Revuelta, Leandro Cerchietti, John P. Leonard	2021	21
11	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes Blood Advances ·Alessia Castellino, Yucai Wang, Melissa C. Larson, Matthew J. Maurer, Brian K. Link, Umar Farooq, Andrew L. Feldman, Sergei Syrbu, Thomas M. Habermann, Jonas Paludo, David J. Inwards, Thomas E. Witzig, Stephen M. Ansell, Cristine Allmer, Susan L. Slager, Jonathon B. Cohen, Peter Martin, James R. Cerhan, Grzegorz S. Nowakowski	2021	13
12	Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom BMC Cancer ·J.F. Lester, Carles Escriu, Sarah Khan, Emma Hudson, T. Mansy, R. John Elford, Pham Minh Ha, Ceri Powell, Juliet Brock, John Conibear, Amy Allen, Rosemary Deem, Xiaohui Zhuo, L C Lane, B. W. Allen, Peter Martin, Xinke Zhang, Vivek Pawar	2021	19
13	The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma British Journal of Haematology ·Nathan Fowler, Loretta J. Nastoupil, Sven de Vos, Mark Knapp, Ian W. Flinn, Robert Chen, Ranjana H. Advani, Sumeet Bhatia, Peter Martin, Raul Mena, R. Eric Davis, Sattva S. Neelapu, Karl Eckert, Jerry Ping, 義雄田原, Darrin M. Beaupre, Jutta K. Neuenburg, M. Lia Palomba	2020	20
14	COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study Journal of Clinical Oncology ·Gagandeep Brar, Laura C. Pinheiro, Minoru Takino, Anna Marie Morisani, Evgeniya Reshetnyak, Orysya Soroka, Frank Chen, Жанболат Тологон, John L. Vaughn, Peter Martin, Doru Paul, Manuel Hidalgo, Manish A. Shah	2020	77
15	Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma Journal of Palliative Medicine ·Kelly M. Trevino, Sarah C. Rutherford, Peter J Sclafani, Yoshiya Teruya, Peter Martin, Holly G. Prigerson, John P. Leonard	2019	8
16	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma Blood ·John Kuruvilla, Michael R. Savona, Rachid Baz, Morten Mau‐Sørensen, Nashat Gabrail, Ramiro Garzon, Richard M. Stone, Michael Wang, Lynn Savoie, Peter Martin, Ian W. Flinn, Meagan A. Jacoby, Thaddeus J. Unger, Jean-Richard Saint-Martin, Tami Rashal, Sharon Friedlander, Robert Carlson, Michael Kauffman, Sharon Shacham, Martin Gutierrez	2017	112
17	A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma Blood ·Peter Martin, Nancy L. Bartlett, KAUSHALENDRA SINGH, María V. Revuelta, Julio C. Chávez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Lei Zhang, رضا قرآنی, Chengqing Wu, John P. Leonard, Leandro Cerchietti	2017	7
18	Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study Blood ·Jia Ruan, Peter Martin, Paul J. Christos, Leandro Cerchietti, Bijal Shah, Stephen J. Schuster, Wayne Tam, Á Rodríguez, David M. Hyman, María Nieves Calvo Vidal, J. Park, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, Morton Coleman, John P. Leonard	2017	7
19	Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma Cancer Discovery ·David Chiron, Maurizio Di Liberto, Peter Martin, Xiangao Huang, Jeff P. Sharman, Pedro Blecua, Susan Mathew, Priyanka Vijay, Ken Eng, Siraj M. Ali, Amy J. Johnson, Betty Chang, Scott Ely, Olivier Elemento, Christopher E. Mason, John P. Leonard, Selina Chen‐Kiang	2014	204
20	Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma Journal of Clinical Oncology ·Peter Martin, Amy Chadburn, Paul J. Christos, 陆恒炜, Richard R. Furman, Jia Ruan, Rebecca Elstrom, Rubén Niesvizky, Scott Ely, Maurizio DiLiberto, Ari Melnick, Daniel M. Knowles, Selina Chen‐Kiang, Morton Coleman, John P. Leonard	2009	234

About Peter Martin

Peter Martin is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Gastroenterology, having authored 222 papers that have together received 4.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (162 papers), Chronic Lymphocytic Leukemia Research (86 papers), Viral-associated cancers and disorders (40 papers), CAR-T cell therapy research (29 papers), Sarcoma Diagnosis and Treatment (15 papers), Monoclonal and Polyclonal Antibodies Research (14 papers), Acute Lymphoblastic Leukemia research (11 papers) and CNS Lymphoma Diagnosis and Treatment (10 papers). The work is most often cited by research in Genetics (1.9k citations), Pathology and Forensic Medicine (3.0k citations), Oncology (2.2k citations), Hematology (446 citations) and Neurology (507 citations). Peter Martin has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include John P. Leonard, Morton Coleman, Richard R. Furman, Jia Ruan, Rebecca Elstrom, Scott Ely, Selina Chen‐Kiang, Paul J. Christos, Amy Chadburn and Rubén Niesvizky. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, Blood Advances and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact